09Oct
Caremark Round II: Beware Red Flags in Drug Development
On October 1, 2019, the Delaware Court of Chancery applied the Delaware Supreme Court’s recent decision on Caremark board oversight claims in the context of operating in a highly regulated industry to allow derivative claims to proceed against the...
By:
Goodwin
Related
Where does creativity fit into compliance? In more places than you think. Problem-solving, accountab...
Read More >
When one party to an M&A agreement alleges that the other breached its representations and warrantie...
Read More >
The #MeToo movement’s efforts to protect employees from unlawful harassment continues to resonate a...
Read More >
In Edwards v. Arthur Andersen LLP, 44 Cal. 4th 937 (2008), the California Supreme Court held that co...
Read More >
As discussed in our post from last year, on August 30, 2018, the Eleventh Circuit Court of Appeals r...
Read More >
We have been discussing arbitration agreements in the National Labor Relations Board (NLRB) context ...
Read More >